Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

NERV

Minerva Neurosciences Inc

Last Close
Apr 25 • 04:00PM ET
2.43
Dollar change
-0.09
Percentage change
-3.57 		%
Held by: VTI VXF
Index- P/E- EPS (ttm)-4.65 Insider Own22.26% Shs Outstand6.99M Perf Week-2.80%
Market Cap16.99M Forward P/E- EPS next Y-4.54 Insider Trans0.00% Shs Float5.44M Perf Month-5.45%
Income-30.01M PEG- EPS next Q-1.20 Inst Own35.19% Short Float0.56% Perf Quarter-68.48%
Sales0.00M P/S- EPS this Y22.56% Inst Trans-8.22% Short Ratio0.26 Perf Half Y-50.00%
Book/sh-4.07 P/B- EPS next Y-27.17% ROA-53.59% Short Interest0.03M Perf Year4.29%
Cash/sh5.87 P/C0.41 EPS next 5Y- ROE- 52W Range2.26 - 13.49 Perf YTD-60.49%
Dividend Est.- P/FCF- EPS past 5Y14.92% ROI-56.02% 52W High-81.99% Beta0.24
Dividend TTM- Quick Ratio12.57 Sales past 5Y-20.00% Gross Margin- 52W Low7.56% ATR (14)0.20
Dividend Ex-Date- Current Ratio12.57 EPS Y/Y TTM22.60% Oper. Margin0.00% RSI (14)33.02 Volatility3.73% 5.47%
Employees9 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price11.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q5.37% Payout- Rel Volume0.05 Prev Close2.52
Sales Surprise- EPS Surprise-35.23% Sales Q/Q- EarningsFeb 22 BMO Avg Volume119.19K Price2.43
SMA20-3.37% SMA50-33.39% SMA200-62.43% Trades Volume5,770 Change-3.57%
Date Action Analyst Rating Change Price Target Change
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Feb-27-24 08:11AM
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
(Reuters) -58.82%
08:00AM
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
(GlobeNewswire)
06:31AM
Minerva schizophrenia drug rejected by FDA
(BioPharma Dive)
Feb-22-24 07:41AM
Minerva Neurosciences: Q4 Earnings Snapshot
(Associated Press Finance) -17.61%
07:00AM
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
(GlobeNewswire)
07:47AM Loading…
Nov-07-23 07:47AM
Minerva Neurosciences: Q3 Earnings Snapshot
(Associated Press Finance)
07:30AM
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
(GlobeNewswire)
Oct-20-23 01:22PM
12 Best Performing Biotech Stocks in 2023
(Insider Monkey)
Aug-01-23 07:40AM
Minerva Neurosciences: Q2 Earnings Snapshot
(Associated Press Finance) +9.15%
07:30AM
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
(GlobeNewswire)
Jun-28-23 08:30AM
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
(GlobeNewswire) +69.27%
Jun-09-23 09:55AM
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
(Zacks)
May-18-23 12:00PM
What Makes Minerva Neurosciences (NERV) a New Buy Stock
(Zacks) +10.15%
May-15-23 09:57PM
Q1 2023 Minerva Neurosciences Inc Earnings Call
(Thomson Reuters StreetEvents) -11.42%
07:40AM
Minerva Neurosciences: Q1 Earnings Snapshot
(AP Finance)
07:30AM Loading…
07:30AM
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
(GlobeNewswire)
May-10-23 08:00AM
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
(GlobeNewswire) +13.68%
May-08-23 08:30AM
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
(GlobeNewswire)
May-01-23 07:00AM
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
(GlobeNewswire) +34.29%
Mar-10-23 02:24AM
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript
(Insider Monkey) -8.01%
Mar-08-23 11:12PM
Q4 2022 Minerva Neurosciences Inc Earnings Call
(Thomson Reuters StreetEvents) -7.65%
07:30AM
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
(GlobeNewswire)
Mar-01-23 08:30AM
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
(GlobeNewswire)
Dec-29-22 10:18AM
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
(Zacks) +5.59%
05:30AM
The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application
(American City Business Journals)
Dec-28-22 08:00AM
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
(GlobeNewswire) -39.15%
Nov-09-22 08:00AM
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
(GlobeNewswire) +8.85%
Nov-02-22 08:30AM
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
(GlobeNewswire) +6.52%
Oct-20-22 11:28AM
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
(Zacks)
Oct-17-22 09:18AM
Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate
(Benzinga) -69.55%
08:51AM Loading…
08:51AM
Minerva Neurosciencs to request meeting with FDA about schizophrenia drug
(MarketWatch)
08:30AM
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
(GlobeNewswire)
Sep-26-22 09:21AM
10 Best Biotech Stocks Under $10
(Insider Monkey)
Sep-09-22 04:05PM
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
(GlobeNewswire)
Aug-31-22 06:25PM
The 5 Bestand 5 WorstNasdaq Stocks in August
(Barrons.com) -14.35%
Aug-23-22 12:38PM
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
(Zacks)
Aug-22-22 08:00AM
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
(GlobeNewswire) +47.83%
Aug-12-22 09:55AM
Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher
(Zacks)
Aug-09-22 08:00AM
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
(GlobeNewswire) -23.89%
Jun-22-22 08:58AM
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
(Simply Wall St.) -5.26%
May-04-22 08:30AM
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
(GlobeNewswire)
Apr-07-22 09:57AM
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
(Zacks)
08:30AM
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
(GlobeNewswire)
Mar-21-22 09:52AM
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
(Zacks)
Mar-01-22 09:05AM
Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
07:30AM
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
Feb-28-22 08:30AM
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
(GlobeNewswire)
Dec-01-21 07:44AM
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?
(Simply Wall St.) -6.82%
Nov-08-21 08:45AM
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:30AM
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
Nov-03-21 08:30AM
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
(GlobeNewswire)
Nov-01-21 08:30AM
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
(GlobeNewswire)
Oct-11-21 08:30AM
Minerva Neurosciences Announces Promotion of Geoff Race to President
(GlobeNewswire)
Oct-01-21 07:00AM
15 Stocks Moving in Friday's Pre-Market Session
(Benzinga) -9.20%
Sep-30-21 10:32AM
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
(Benzinga)
08:30AM
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
(GlobeNewswire)
Sep-27-21 08:30AM
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
(Zacks)
Sep-08-21 08:30AM
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
(GlobeNewswire)
Aug-02-21 08:55AM
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
07:30AM
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
Jul-26-21 03:01PM
Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
(Zacks)
08:30AM
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
(GlobeNewswire)
Jun-10-21 08:30AM
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
(GlobeNewswire)
Jun-04-21 05:20AM
What Type Of Shareholders Own The Most Number of Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares?
(Simply Wall St.)
May-28-21 08:00AM
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
(GlobeNewswire)
May-19-21 06:19AM
Minerva Neurosciences (NERV) Enters Overbought Territory
(Zacks) -9.69%
May-17-21 07:57AM
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
(Zacks) +13.65%
May-13-21 09:01AM
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
(Zacks)
May-12-21 02:35PM
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
(Zacks) +15.70%
10:03AM
Minerva (NERV) Soars on Promising Schizophrenia Study Data
(Zacks)
08:30AM
Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining?
(PR Newswire)
07:30AM
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
07:20AM
Minerva Shares Soar on Positive Schizophrenia Drug Trial
(TheStreet.com)
06:59AM
Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning
(Benzinga)
06:45AM
Minerva Neurosciences, Inc. to Host Earnings Call
(ACCESSWIRE)
May-11-21 04:15PM
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension
(GlobeNewswire)
May-05-21 05:10PM
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
(GlobeNewswire)
Apr-07-21 08:46AM
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?
(Zacks)
Apr-05-21 09:31AM
Can Mixed Fundamentals Have A Negative Impact on Minerva Neurosciences, Inc. (NASDAQ:NERV) Current Share Price Momentum?
(Simply Wall St.)
Mar-08-21 12:30PM
Minerva Neurosciences (NERV) Q4 2020 Earnings Call Transcript
(Motley Fool) +11.54%
07:30AM
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
(GlobeNewswire)
05:30AM
Minerva Neurosciences, Inc. to Host Earnings Call
(ACCESSWIRE)
Mar-06-21 10:57AM
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
(Benzinga)
Mar-01-21 08:30AM
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
(GlobeNewswire)
Feb-08-21 02:30PM
CLASS ACTION UPDATE for NERV, OTGLY and QS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
(ACCESSWIRE)
01:20PM
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses to Contact the Firm
(ACCESSWIRE)
12:30PM
Lawsuits Filed Against IRTC, NERV and BTBT - Jakubowitz Law Pursues Shareholders Claims
(ACCESSWIRE)
11:30AM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(PR Newswire)
11:13AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Minerva Neurosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2021 - NERV
(Newsfile)
11:00AM
NERV Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Minerva Neurosciences, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: February 8, 2021
(ACCESSWIRE)
09:43AM
NERV DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline - NERV
(Newsfile)
06:20AM
SHAREHOLDER ALERT: NERV TCDA BTBT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
(ACCESSWIRE)
12:45AM
FEBRUARY 8 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses to Contact the Firm
(ACCESSWIRE)
Feb-07-21 01:12PM
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(Newsfile)
10:30AM
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of NERV, QS and AZN
(ACCESSWIRE)
Feb-06-21 01:10PM
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(Newsfile)
10:00AM
MINERVA FINAL DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline NERV
(GlobeNewswire)
07:15AM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(ACCESSWIRE)
Feb-05-21 09:15PM
NERV FINAL DEADLINE MONDAY: ROSEN, A RANKED AND LEADING FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important February 8 Deadline - NERV
(PR Newswire)
09:00PM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Minerva Neurosciences, Inc. and Encourages Investors to Contact the Firm
(Business Wire)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Luthringer RemyCEOMay 02 '23Sale3.763,64113,69068,994May 02 06:15 PM
Luthringer RemyCEOMay 01 '23Sale3.8523,75391,44972,635May 02 06:15 PM
Race GeoffPresidentMay 01 '23Sale3.8522,08285,01651,324May 02 06:14 PM
Ahlholm Frederick WSVP, CFO and SecretaryMay 01 '23Sale4.483,58016,03817,518May 02 06:13 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

AMRN

Amarin Corp ADR

Last Close
Apr 25 • 04:00PM ET
0.8601
Dollar change
-0.0185
Percentage change
-2.11 		%
AMRN Amarin Corp ADR daily Stock Chart
Index- P/E- EPS (ttm)-0.15 Insider Own0.38% Shs Outstand408.82M Perf Week-1.34%
Market Cap351.63M Forward P/E- EPS next Y-0.13 Insider Trans-1.25% Shs Float407.25M Perf Month-0.68%
Income-59.26M PEG- EPS next Q-0.03 Inst Own23.62% Short Float3.89% Perf Quarter-31.74%
Sales308.22M P/S1.14 EPS this Y6.67% Inst Trans-7.25% Short Ratio9.56 Perf Half Y13.13%
Book/sh1.35 P/B0.64 EPS next Y9.52% ROA-6.90% Short Interest15.84M Perf Year-32.80%
Cash/sh0.79 P/C1.09 EPS next 5Y38.90% ROE-10.33% 52W Range0.65 - 1.49 Perf YTD-1.14%
Dividend Est.- P/FCF- EPS past 5Y17.93% ROI-10.57% 52W High-42.08% Beta1.98
Dividend TTM- Quick Ratio1.80 Sales past 5Y14.60% Gross Margin53.00% 52W Low32.12% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.80 EPS Y/Y TTM44.82% Oper. Margin-18.41% RSI (14)38.75 Volatility3.65% 6.53%
Employees275 Debt/Eq0.02 Sales Y/Y TTM-16.19% Profit Margin-19.23% Recom3.00 Target Price1.08
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-780.95% Payout- Rel Volume0.43 Prev Close0.88
Sales Surprise12.76% EPS Surprise62.83% Sales Q/Q-17.11% EarningsMay 01 BMO Avg Volume1.66M Price0.86
SMA20-9.74% SMA50-13.18% SMA200-11.44% Trades Volume711,770 Change-2.11%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Underweight
Oct-25-23Downgrade Jefferies Buy → Hold $3 → $1
Jan-06-23Upgrade Jefferies Hold → Buy $1.30 → $3
May-06-22Downgrade JP Morgan Neutral → Underweight
May-05-22Downgrade SVB Leerink Outperform → Mkt Perform $10 → $3
May-05-22Downgrade H.C. Wainwright Buy → Neutral $10 → $3
May-04-22Downgrade Northland Capital Outperform → Market Perform
May-12-21Downgrade Goldman Neutral → Sell $6 → $5
Sep-29-20Resumed JP Morgan Neutral
Aug-26-20Initiated Piper Sandler Overweight $21
Show Previous Ratings
Apr-24-24 02:00PM
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
(GlobeNewswire)
Apr-22-24 08:00AM
Amarin Announces Results of Annual General Meeting of Shareholders
(GlobeNewswire)
Apr-15-24 08:00AM
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
(GlobeNewswire)
Apr-08-24 08:00AM
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
(GlobeNewswire)
06:30AM
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
(PR Newswire)
03:30PM Loading…
Apr-06-24 03:30PM
New REDUCE-IT Analyses Show VASCEPA /VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
(GlobeNewswire)
Apr-04-24 01:20PM
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
(Zacks)
Apr-03-24 04:13PM
Why Amarin Stock Was Rocketing Higher on Wednesday
(Motley Fool) +7.07%
08:00AM
Amarin Provides Update on VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio in Europe
(GlobeNewswire)
Mar-25-24 08:00AM
Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
(GlobeNewswire)
Mar-01-24 09:30AM
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
(Zacks)
08:39AM
Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-29-24 03:30PM
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
(Motley Fool) -18.94%
07:37AM
Amarin: Q4 Earnings Snapshot
(Associated Press Finance)
07:34AM
Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition
(GuruFocus.com)
07:00AM Loading…
07:00AM
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Feb-15-24 08:00AM
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
(GlobeNewswire)
Jan-22-24 07:30AM
Amarin Chairman & CEO Issue Letter to Shareholders
(GlobeNewswire) +9.52%
Jan-12-24 09:40AM
Are Medical Stocks Lagging Amarin (AMRN) This Year?
(Zacks)
Jan-11-24 09:34AM
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
(Zacks) -9.30%
Jan-10-24 07:02PM
Why Amarin Stock Skyrocketed Today
(Motley Fool) +32.87%
07:00AM
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
(GlobeNewswire)
Dec-26-23 07:13PM
13 Most Promising Small-Cap Stocks According to Analysts
(Insider Monkey)
Dec-11-23 08:00AM
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-05-23 12:00PM
What Makes Amarin (AMRN) a New Buy Stock
(Zacks)
Nov-12-23 09:00AM
New REDUCE-IT Analyses Show VASCEPA (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
(GlobeNewswire)
Nov-02-23 10:58AM
Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript
(Insider Monkey) -5.47%
Nov-01-23 12:30PM
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
(Motley Fool)
12:03PM
Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates
(Zacks)
09:30AM
Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
(Zacks)
09:25AM Loading…
09:25AM
Amarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-Year
(GuruFocus.com)
07:30AM
Amarin: Q3 Earnings Snapshot
(Associated Press Finance)
07:00AM
Amarin Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-31-23 12:00PM
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
(GlobeNewswire)
Oct-26-23 08:00AM
Latest Research Evaluating VASCEPA /VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
(GlobeNewswire)
Oct-23-23 10:08AM
12 Best Penny Stocks to Buy Under $1
(Insider Monkey)
Oct-19-23 08:00AM
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
(GlobeNewswire)
Sep-12-23 08:00AM
Amarin to Present at the 2023 Cantor Global Healthcare Conference
(GlobeNewswire)
Aug-24-23 09:29AM
11 Best Long-Term Penny Stocks to Buy Now
(Insider Monkey)
Aug-19-23 11:22AM
Buffett goes big on homebuilders: Insider trades & hedge funds weekly
(Investing.com)
Aug-09-23 04:05PM
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
(GlobeNewswire)
Aug-08-23 07:00AM
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
(GlobeNewswire)
Aug-07-23 07:00AM
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
(GlobeNewswire)
Aug-03-23 11:22AM
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
(Zacks)
Aug-02-23 07:33AM
Amarin: Q2 Earnings Snapshot
(AP Finance)
07:11AM
Amarin Reports Second Quarter 2023 Financial Results
(GlobeNewswire)
Jul-31-23 08:00AM
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
(GlobeNewswire)
Jul-28-23 02:56PM
10 Best Small Cap Pharma Stocks to Buy
(Insider Monkey) +6.25%
Jul-26-23 08:00AM
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
(GlobeNewswire)
Jul-25-23 04:05PM
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
(GlobeNewswire)
Jul-20-23 08:00AM
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
(GlobeNewswire)
Jul-19-23 12:58PM
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
(Zacks) -24.48%
11:19AM
Why Amarin Stock Is Sinking Today
(Motley Fool)
Jul-18-23 04:16PM
Amarin Appoints Patrick Holt as President and Chief Executive Officer
(GlobeNewswire) +9.16%
04:15PM
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
(GlobeNewswire)
Jul-05-23 11:43AM
Amarin (NASDAQ:AMRN) shareholders have endured a 83% loss from investing in the stock three years ago
(Simply Wall St.)
Jun-21-23 09:00AM
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
(GlobeNewswire)
Jun-08-23 11:07AM
Investors Aren't Buying Amarin Corporation plc's (NASDAQ:AMRN) Revenues
(Simply Wall St.)
Jun-01-23 04:30PM
Amarin to Present at Two Upcoming Investor Conferences
(GlobeNewswire)
06:00AM
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
(GlobeNewswire)
May-23-23 09:50AM
3 Biotech Stocks to Avoid Like the Plague
(InvestorPlace)
May-12-23 11:00AM
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
(GlobeNewswire)
May-03-23 02:00PM
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
(Motley Fool)
01:47PM
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
(Zacks)
07:41AM
Amarin: Q1 Earnings Snapshot
(AP Finance)
07:00AM
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-02-23 01:32PM
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
(Zacks)
Apr-19-23 08:00AM
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
(GlobeNewswire)
Apr-17-23 07:00AM
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver OConnor to Companys Board of Directors
(GlobeNewswire)
Apr-13-23 10:18AM
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
(Simply Wall St.)
Apr-12-23 09:18AM
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
(Zacks)
Apr-04-23 03:53PM
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
(Motley Fool)
08:00AM
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
(GlobeNewswire)
Mar-16-23 08:00AM
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
(GlobeNewswire) +7.24%
Mar-06-23 04:05PM
Amarin Announces Board Departures
(GlobeNewswire)
09:37AM
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
(Benzinga)
08:00AM
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
(GlobeNewswire)
Mar-05-23 10:21AM
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
(GlobeNewswire)
Mar-03-23 11:09AM
Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-02-23 01:23PM
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
(Zacks) -5.34%
11:44AM
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
(Zacks)
05:55AM
Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021)
(Simply Wall St.)
Mar-01-23 11:02AM
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
(Zacks)
11:00AM
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
(Motley Fool)
07:00AM
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Feb-28-23 11:11AM
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
(Zacks) +10.33%
10:39AM
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
(Business Wire)
10:38AM
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
(GlobeNewswire)
08:00AM
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
(GlobeNewswire)
Feb-27-23 04:29PM
Amarin Sets the Record Straight on Sarissas Latest Misstatements
(GlobeNewswire)
08:00AM
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
(GlobeNewswire)
07:15AM
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
(Business Wire)
Feb-24-23 11:52AM
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
(Zacks)
Feb-22-23 04:50PM
Hikma accuses Amarin of suppressing generic versions of heart pill
(Reuters)
08:00AM
Amarin to Present at Cowen's 43rd Annual Health Care Conference
(GlobeNewswire)
Feb-21-23 08:30AM
Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change
(Business Wire)
08:00AM
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
(GlobeNewswire)
Feb-20-23 01:00PM
Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change
(Business Wire)
Feb-17-23 09:03AM
Amarin Urges Shareholders to Vote Against Sarissas Harmful Proposals at Upcoming General Meeting IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
(GlobeNewswire)
07:30AM
Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders
(Business Wire)
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holt PatrickPresident and CEOJan 22 '24Buy1.0914,42615,724314,426Jan 24 04:31 PM
Ketchum Steven BChief Scientific OfficerDec 12 '23Sale0.7934,13126,963566,100Dec 14 06:35 PM
Holt PatrickPresident and CEOAug 16 '23Buy1.04300,000312,315300,000Aug 16 07:51 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.